Home Evaluation of a commercially available rapid urinary porphobilinogen test
Article
Licensed
Unlicensed Requires Authentication

Evaluation of a commercially available rapid urinary porphobilinogen test

  • Michael Vogeser EMAIL logo and Thomas Stauch
Published/Copyright: May 31, 2011

Abstract

Background: Demonstration of substantially increased urinary excretion of porphobilinogen is the cornerstone of diagnosing acute porphyria crisis. Because porphobilinogen testing is not implemented on clinical chemistry analysers, respective analyses are available in rather few clinical laboratories. The aim of this study was to critically describe and to evaluate a semi-quantitative rapid test for urinary porphobilinogen determination which is commercially available and recommended by the American Porphyria Foundation.

Methods: Urinary samples from patients with acute intermittent porphyria and control samples were analysed and the semi-quantitative results were compared with the results obtained by a manual quantitative spectrophotometric method.

Results: In all 32 samples studied, acceptable agreement between the results of the rapid test and the quantitative test was observed. Handling of the test was found to be convenient.

Conclusions: The assay was found to be reliable and has the potential to increase the availability of porphobilinogen testing in the field.


Corresponding author: Prof. Dr. med. Michael Vogeser, Institute of Clinical Chemistry, University of Munich, Marchioninistr. 15, 81375 München, Germany Phone: +49-89-7095-3221, Fax: +49-89-7095-8888

Received: 2011-1-25
Accepted: 2011-3-28
Published Online: 2011-05-31
Published in Print: 2011-09-01

©2011 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. Editorial
  2. Athlete's biological passport: to test or not to test?
  3. Review
  4. Prognostic value of cystatin C in acute coronary syndromes: enhancer of atherosclerosis and promising therapeutic target
  5. Opinion Papers
  6. The function of oxalic acid in the human metabolism
  7. Current limitations of the Athlete's Biological Passport use in sports
  8. Limits and pitfalls of Athlete's Biological Passport
  9. The Athlete Biological Passport from the perspective of an anti-doping organization
  10. Perspectives
  11. Genetics of infectious diseases: hidden etiologies and common pathways
  12. Guidelines and Recommendations
  13. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 °C. Part 9: Reference procedure for the measurement of catalytic concentration of alkaline phosphatase
  14. Genetics and Molecular Diagnostics
  15. A template for mutational data analysis of the CFTR gene
  16. High resolution melting analysis to genotype the most common variants in the HFE gene
  17. General Clinical Chemistry and Laboratory Medicine
  18. Bayesian analysis of an international ELISA comparability study
  19. Inflammatory markers in preeclamptic patients
  20. Pre-analytical effects of different lithium heparin plasma separation tubes in the routine clinical chemistry laboratory
  21. Pre-acquisition system assessment of the Sysmex® Coagulation System CS-2100i and comparison with end-user verification; a model for the regional introduction of new analysers and methods
  22. Evaluation of a commercially available rapid urinary porphobilinogen test
  23. Reference Values and Biological Variations
  24. Reference intervals and age and gender dependency for arterial blood gases and electrolytes in adults
  25. Within-subject biological variation of glucose and HbA1c in healthy persons and in type 1 diabetes patients
  26. Determinants of oxidative stress related to gender: relevance of age and smoking habit
  27. Soluble ST2 is not independently associated with androgen and estrogen status in healthy males and females
  28. Infectious Diseases
  29. Development of candidate reference reagent for HIV-1 RNA and comparison analysis for different HIV-1 RNA quantitative assay
  30. Prognostic value of serum angiotensin-converting enzyme activity for outcome of community-acquired pneumonia
  31. The evaluation of colloidal gold immunochromatographic assay (GICA) for rapid diagnosis of influenza A disease
  32. Cardiovascular Disease
  33. N-terminal pro-B-type natriuretic peptide in early and advanced phases of obesity
  34. Vaspin plasma concentrations and mRNA expressions in patients with stable and unstable angina pectoris
  35. Prospective study of first stroke in relation to plasma homocysteine and MTHFR 677C>T and 1298A>C genotypes and haplotypes – evidence for an association with hemorrhagic stroke
  36. Letters to the Editor
  37. Evaluation of the analytical performance of the Beckman Coulter AU680 automated analytical system based on quality specifications for allowable performance derived from biological variation
  38. Collagen peptides, interstitial remodelling and sudden cardiac death in hypertrophic cardiomyopathy
  39. Erratum
  40. Modified phosphatidylserine-dependent antiprothrombin ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies
Downloaded on 10.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2011.605/html
Scroll to top button